Servicio de Neurología, Instituto Peruano de Neurociencias, Lima, Perú.
Unidad de Diagnóstico de Deterioro Cognitivo y Prevención de Demencia, Instituto Peruano de Neurociencias, Lima, Perú.
Am J Alzheimers Dis Other Demen. 2022 Jan-Dec;37:15333175221104354. doi: 10.1177/15333175221104354.
The Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale is a versatile functional assessment tool for patients with Alzheimer's disease (ad). We evaluated its performance in controls, Peruvians with MCI or AD.
A cross-sectional study of older adults attending a neurology institute in Lima (Peru) with mild cognitive impairment (MCI), ad or cognitively healthy. Test-retest reliability (intraclass correlation coefficient, ICC; internal consistency, Cronbach's alpha) and validity were assessed.
We enrolled 276 individuals (ad: 113, MCI: 68, controls: 95) with no age, sex, educational level, and depressive symptom differences. Reliability was ideal (ICC: .996), and Cronbach's alpha was adequate (.937). The ADCS-ADL could not differentiate MCI from controls but did differentiate ad severity. The ADCS-ADL correlated highly with nearly all tools.
The ADCS-ADL scale is reliable in a population with ad in Lima, Peru. Future work may validate a tool for Peruvians with lower educational levels.
阿尔茨海默病合作研究-日常生活活动（ADCS-ADL）量表是一种用于评估阿尔茨海默病（AD）患者的多功能功能评估工具。我们评估了其在对照者、秘鲁认知障碍（MCI）或 AD 患者中的表现。
对利马（秘鲁）神经病学研究所的老年参与者进行了一项横断面研究，包括轻度认知障碍（MCI）、AD 或认知健康者。评估了其测试-重测信度（组内相关系数，ICC；内部一致性，Cronbach's alpha）和效度。
我们共纳入了 276 名参与者（AD：113 名，MCI：68 名，对照组：95 名），他们在年龄、性别、教育程度和抑郁症状方面没有差异。信度理想（ICC：.996），Cronbach's alpha 也足够高（.937）。ADCS-ADL 无法区分 MCI 与对照组，但可以区分 AD 的严重程度。ADCS-ADL 与几乎所有工具都高度相关。
ADCS-ADL 量表在秘鲁利马的 AD 人群中具有可靠性。未来的研究可能会验证一种针对教育程度较低的秘鲁人的工具。
